Future therapy of hepatitis CMCHUTCHISON, John G; PATEL, Keyur.Hepatology (Baltimore, Md.). 2002, Vol 36, Num 5, pp S245-S252, issn 0270-9139, SUP1Conference Paper

Diagnosis and treatment of chronic hepatitis C infectionPATEL, Keyur; MUIR, Andrew J; MCHUTCHISON, John G et al.BMJ. British medical journal (International ed.). 2006, Vol 332, Num 7548, pp 1013-1017, issn 0959-8146, 5 p.Article

Hepatitis C. Development of new drugs and clinical trials: Promises and pitfallsPAWLOTSKY, Jean-Michel; MCHUTCHISON, John G.Hepatology (Baltimore, Md.). 2004, Vol 39, Num 2, pp 554-567, issn 0270-9139, 14 p.Article

Hepatitis C advances in antiviral therapy: What is accepted treatment now?MCHUTCHISON, John G.Journal of gastroenterology and hepatology. 2002, Vol 17, Num 4, pp 431-441, issn 0815-9319Conference Paper

Will IL28B Polymorphism Remain Relevant in the Era of Direct-Acting Antiviral Agents for Hepatitis C Virus?THOMPSON, Alexander J; MCHUTCHISON, John G.Hepatology (Baltimore, Md.). 2012, Vol 56, Num 1, pp 373-381, issn 0270-9139, 9 p.Article

LKM-positive autoimmune hepatitis in the western United States : A case seriesDUCHINI, Andrea; MCHUTCHISON, John G; POCKROS, Paul J et al.The American journal of gastroenterology. 2000, Vol 95, Num 11, pp 3238-3241, issn 0002-9270Article

IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV TherapiesCLARK, Paul J; THOMPSON, Alex J; MCHUTCHISON, John G et al.The American journal of gastroenterology. 2011, Vol 106, Num 1, pp 38-45, issn 0002-9270, 8 p.Article

Directly acting antivirals for the treatment of patients with hepatitis C infection : A clinical development update addressing key future challengesTHOMPSON, Alex; PATEL, Keyur; TILLMAN, Hans et al.Journal of hepatology. 2009, Vol 50, Num 1, pp 184-194, issn 0168-8278, 11 p.Article

The face of future hepatitis C antiviral drug development : Recent biological and virologic advances and their translation to drug development and clinical practiceMCHUTCHISON, John G; BARTENSCHLAGER, Ralf; PATEL, Keyur et al.Journal of hepatology. 2006, Vol 44, Num 2, pp 411-421, issn 0168-8278, 11 p.Article

Future trends in managing hepatitis CMCHUTCHISON, John G; DEV, Anouk T.Gastroenterology clinics of North America. 2004, Vol 33, Num 1S, pp xix-xx, issn 0889-8553, 12 p., SUPArticle

Estimating future hepatitis C morbidity, mortality, and costs in the United StatesWONG, John B; MCQUILLAN, Geraldine M; MCHUTCHISON, John G et al.American journal of public health (1971). 2000, Vol 90, Num 10, pp 1562-1569, issn 0090-0036Article

Abundant Drug-Resistant NS3 Mutants Detected by Deep Sequencing in Hepatitis C Virus-Infected Patients Undergoing NS3 Protease Inhibitor MonotherapySVAROVSKAIA, Evguenia S; MARTIN, Ross; MCHUTCHISON, John G et al.Journal of clinical microbiology (Print). 2012, Vol 50, Num 10, pp 3267-3274, issn 0095-1137, 8 p.Article

Use of Thrombopoietic Agents for the Thrombocytopenia of Liver DiseaseTILLMANN, Hans L; MCHUTCHISON, John G.Seminars in hematology. 2010, Vol 47, Num 3, pp 266-273, issn 0037-1963, 8 p.Article

Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatmentSOLER, Muriel; MCHUTCHISON, John G; KWOH, T. Jesse et al.Antiviral therapy (London). 2004, Vol 9, Num 6, pp 953-968, issn 1359-6535, 16 p.Article

Albinterferon α-2b : a genetic fusion protein for the treatment of chronic hepatitis CMANI SUBRAMANIAN, G; FISCELLA, Michele; LAMOUSE-SMITH, Araba et al.Nature biotechnology (Print). 2007, Vol 25, Num 12, pp 1411-1419, issn 1087-0156, 9 p.Article

Aspergillosis in liver transplant recipients: Successful treatment and improved survival using a multistep approachDUCHINI, Andrea; REDFIELD, David C; MCHUTCHISON, John G et al.Southern medical journal (Birmingham). 2002, Vol 95, Num 8, pp 897-899, issn 0038-4348Article

Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical modelBEKKERING, Frank C; STALGIS, Carlos; MCHUTCHISON, John G et al.Hepatology (Baltimore, Md.). 2001, Vol 33, Num 2, pp 419-423, issn 0270-9139Article

A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patientsLAWITZ, Eric J; HILL, John M; RODRIGUEZ-TORRES, Maribel et al.Antiviral therapy (London). 2013, Vol 18, Num 3, pp 311-319, issn 1359-6535, 9 p.Article

Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionLAWITZ, Eric; MANGIA, Alessandra; JACOBSON, Ira M et al.The New England journal of medicine. 2013, Vol 368, Num 20, pp 1878-1887, issn 0028-4793, 10 p.Article

Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patientsTHOMPSON, Alexander J; CLARK, Paul J; NAGGIE, Susanna et al.Journal of hepatology. 2012, Vol 56, Num 2, pp 313-319, issn 0168-8278, 7 p.Article

Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1RUNYAN JIN; LING CAI; MING TAN et al.The American journal of gastroenterology. 2012, Vol 107, Num 11, pp 1675-1683, issn 0002-9270, 9 p.Article

Telaprevir for Previously Treated Chronic HCV InfectionMCHUTCHISON, John G; MANNS, Michael P; BSHARAT, Mohammad et al.The New England journal of medicine. 2010, Vol 362, Num 14, pp 1292-1303, issn 0028-4793, 12 p.Article

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionMCHUTCHISON, John G; EVERSON, Gregory T; GORDON, Stuart C et al.The New England journal of medicine. 2009, Vol 360, Num 18, pp 1827-1838, issn 0028-4793, 12 p.Article

Strategies for managing anemia in hepatitis C patients undergoing antiviral therapyMCHUTCHISON, John G; MANNS, Michael P; BROWN, Robert S et al.The American journal of gastroenterology. 2007, Vol 102, Num 4, pp 880-889, issn 0002-9270, 10 p.Article

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virusMCHUTCHISON, John G; BACON, Bruce R; LEKSTROM-HIMES, Julie A et al.Hepatology (Baltimore, Md.). 2007, Vol 46, Num 5, pp 1341-1349, issn 0270-9139, 9 p.Article